In 2013, Jensen et al. [150] demonstrated that injection of NU-0129 reduced the expression of Bcl2L12 in glioblastoma leading to a decrease in tumor progression in xenografted mice, without adverse side effects. This evidence concerns the gene BCL2L12 and neoplasm.